BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35454911)

  • 1. Male Breast Cancer: From Molecular Genetics to Clinical Management.
    Pensabene M; Von Arx C; De Laurentiis M
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Landscape of Male Breast Cancer.
    Campos FAB; Rouleau E; Torrezan GT; Carraro DM; Casali da Rocha JC; Mantovani HK; da Silva LR; Osório CABT; Moraes Sanches S; Caputo SM; Santana Dos Santos E
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
    Rizzolo P; Zelli V; Silvestri V; Valentini V; Zanna I; Bianchi S; Masala G; Spinelli AM; Tibiletti MG; Russo A; Varesco L; Giannini G; Capalbo C; Calistri D; Cortesi L; Viel A; Bonanni B; Azzollini J; Manoukian S; Montagna M; Peterlongo P; Radice P; Palli D; Ottini L
    Int J Cancer; 2019 Jul; 145(2):390-400. PubMed ID: 30613976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Rolfes M; Borde J; Möllenhoff K; Kayali M; Ernst C; Gehrig A; Sutter C; Ramser J; Niederacher D; Horváth J; Arnold N; Meindl A; Auber B; Rump A; Wang-Gohrke S; Ritter J; Hentschel J; Thiele H; Altmüller J; Nürnberg P; Rhiem K; Engel C; Wappenschmidt B; Schmutzler RK; Hahnen E; Hauke J
    Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetrance of male breast cancer susceptibility genes: a systematic review.
    Chamseddine RS; Wang C; Yin K; Wang J; Singh P; Zhou J; Robson ME; Braun D; Hughes KS
    Breast Cancer Res Treat; 2022 Jan; 191(1):31-38. PubMed ID: 34642874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.
    Al Saati A; Vande Perre P; Plenecassagnes J; Gilhodes J; Monselet N; Cabarrou B; Lignon N; Filleron T; Telly D; Perello-Lestrade E; Feillel V; Staub A; Martinez M; Chipoulet E; Collet G; Thomas F; Gladieff L; Toulas C
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hereditary breast carcinomas pathologist's perspective].
    Vincent-Salomon A; Bataillon G; Djerroudi L
    Ann Pathol; 2020 Apr; 40(2):78-84. PubMed ID: 32241645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling.
    Calip GS; Kidd J; Bernhisel R; Cox HC; Saam J; Rauscher GH; Lancaster JM; Hoskins KF
    Breast Cancer Res Treat; 2021 Jan; 185(1):195-204. PubMed ID: 32918117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
    Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of
    Rizzolo P; Silvestri V; Bucalo A; Zelli V; Valentini V; Catucci I; Zanna I; Masala G; Bianchi S; Spinelli AM; Tommasi S; Tibiletti MG; Russo A; Varesco L; Coppa A; Calistri D; Cortesi L; Viel A; Bonanni B; Azzollini J; Manoukian S; Montagna M; Radice P; Palli D; Peterlongo P; Ottini L
    Front Oncol; 2018; 8():583. PubMed ID: 30564557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Male breast cancer is not congruent with the female disease.
    Fentiman IS
    Crit Rev Oncol Hematol; 2016 May; 101():119-24. PubMed ID: 26989051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case.
    Vietri MT; Caliendo G; D'Elia G; Resse M; Casamassimi A; Minucci PB; Cioffi M; Molinari AM
    Eur J Med Genet; 2020 Jun; 63(6):103883. PubMed ID: 32058061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients.
    Tedaldi G; Tebaldi M; Zampiga V; Cangini I; Pirini F; Ferracci E; Danesi R; Arcangeli V; Ravegnani M; Martinelli G; Falcini F; Ulivi P; Calistri D
    Diagnostics (Basel); 2020 Apr; 10(5):. PubMed ID: 32365798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.
    Strojnik K; Krajc M; Dragos VS; Stegel V; Novakovic S; Blatnik A
    Breast Cancer Res Treat; 2021 Aug; 188(3):811-820. PubMed ID: 33891299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.
    Njoroge SW; Burgess KR; Cobleigh MA; Alnajar HH; Gattuso P; Usha L
    Breast Cancer Res Treat; 2017 Nov; 166(1):315-319. PubMed ID: 28702897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas.
    Deb S; Jene N; ; Fox SB
    BMC Cancer; 2012 Nov; 12():510. PubMed ID: 23146383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMSY copy number variation in male breast cancers characterized for BRCA1 and BRCA2 mutations.
    Navazio AS; Rizzolo P; Silvestri V; Valentini V; Zelli V; Zanna I; Masala G; Bianchi S; Tommasi S; Palli D; Ottini L
    Breast Cancer Res Treat; 2016 Nov; 160(1):181-186. PubMed ID: 27628328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.